IMMUNOLOGICAL MARKERS OF LONG-TERM EFFECTS OF TREATMENT IN PATIENTS WITH MILD COGNITIVE IMPAIRMENT

S A Krynskiy; I K Malashenkova; N A Hailov; D P Ogurtsov; E I Chekulaeva; E V Ponomareva; S I Gavrilova; N A Didkovsky

Medical academic journal ›› 2019, Vol. 19 ›› Issue (1S) :84 -86.

Articles

oration

IMMUNOLOGICAL MARKERS OF LONG-TERM EFFECTS OF TREATMENT IN PATIENTS WITH MILD COGNITIVE IMPAIRMENT

Author information +

History +

Abstract

The goal of this research was to study the clinical efficacy of course-based neurotrophic therapy in mild cognitive impairment (MCI) and the effect of therapy on immune parameters in patients, and to assess the prognostic value of the dynamics of immune parameters during the year after treatment. 20 patients with MCI receiving intravenous Cerebrolysin (20 infusions of 30 ml with increasing dose during the first four days) were examined. Neuropsychological and immunological examination was carried out immediately before the study, after 3 months., 6 months and after 1 year after the end of treatment. It was found that after therapy, patients had a long-term decrease in the severity of systemic inflammatory response, and that marked signs of systemic inflammation at the beginning of follow-up combined with a persistent decrease in the level of immunoglobulin G in dynamics were prognostic markers of MCI progression. In conclusion, it wass shown that neurotrophic therapy has a good clinical effect and has a favorable immunomodulatory effect in aMCI, and the relationship between the dynamics of humoral immunity and systemic inflammation and the risk of progression of cognitive impairment in patients within 1 year after therapy was established.

Keywords

Alzheimer’s disease / immunoglobulin G / mild cognitive impairment / systemic inflammation / IL-8 / IL-8

Cite this article

Download citation ▾

S A Krynskiy, I K Malashenkova, N A Hailov, D P Ogurtsov, E I Chekulaeva, E V Ponomareva, S I Gavrilova, N A Didkovsky. IMMUNOLOGICAL MARKERS OF LONG-TERM EFFECTS OF TREATMENT IN PATIENTS WITH MILD COGNITIVE IMPAIRMENT. Medical academic journal, 2019, 19(1S): 84-86 DOI:

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Manly JJ, Tang MX, Schupf N, et al. Frequency and course of mild cognitive impairment in a multiethnic community. Ann Neurol. 2008;63(4):494-506. https://doi.org/10.1002/ana.21326.

[2]	Palmer K, Fratiglioni L, Winblad B. What is mild cognitive impairment? Variations in definitions and evolution of nondemented persons with cognitive impairment. Acta Neurol Scand. 2003;179:14-20.

[3]	Skaper SD, Facci L, Zusso M, Giusti P. An Inflammation-Centric View of Neurological Disease: Beyond the Neuron. Front Cell Neurosci. 2018;12:72. eCollection 2018. https://doi.org/10.3389/fncel.2018.00072.

[4]	Petersen RC, Touchon J. Consensus on mild cognitive impairment. Research and Practice in Alzheimer’s Disease, E.A.D.C./A.D.C.S. Joint Meeting (Serdi Publisher, Paris). 2005;10:24-32.